Despite Passionate Patient Accounts, FDA Sees No Evidence of 'Super-Responders' in Avastin Trials

If Genentech produces data showing substantial benefit in a subset of patients, "a new science-based indication could be approved," an FDA official said. "Until that time, it is not appropriate for the drug to continue to be approved for the treatment of breast cancer when the totality of the available data does not support such an approval."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.